Vanguard Group’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $669M | Buy |
8,803,203
+514,204
| +6% | +$37.4M | 0.01% | 882 |
|
|
2025
Q3 | $509M | Sell |
8,288,999
-558,468
| -6% | -$29.1M | 0.01% | 1057 |
|
|
2025
Q2 | $432M | Buy |
8,847,467
+240,095
| +3% | +$11.4M | 0.01% | 1112 |
|
|
2025
Q1 | $439M | Sell |
8,607,372
-571,450
| -6% | -$28.5M | 0.01% | 1067 |
|
|
2024
Q4 | $414M | Buy |
9,178,822
+53,688
| +0.6% | +$2.3M | 0.01% | 1148 |
|
|
2024
Q3 | $339M | Buy |
9,125,134
+151,363
| +2% | +$5.07M | 0.01% | 1257 |
|
|
2024
Q2 | $274M | Sell |
8,973,771
-395,243
| -4% | -$12.8M | 0.01% | 1320 |
|
|
2024
Q1 | $273M | Buy |
9,369,014
+568,171
| +6% | +$15.9M | 0.01% | 1333 |
|
|
2023
Q4 | $243M | Buy |
8,800,843
+855,354
| +11% | +$19.6M | 0.01% | 1399 |
|
|
2023
Q3 | $178M | Buy |
7,945,489
+393,012
| +5% | +$14.6M | ﹤0.01% | 1491 |
|
|
2023
Q2 | $307M | Sell |
7,552,477
-35,305
| -0.5% | -$1.73M | 0.01% | 1230 |
|
|
2023
Q1 | $368M | Buy |
7,587,782
+248,262
| +3% | +$11.3M | 0.01% | 1081 |
|
|
2022
Q4 | $280M | Buy |
7,339,520
+127,800
| +2% | +$5.31M | 0.01% | 1234 |
|
|
2022
Q3 | $362M | Buy |
7,211,720
+28,028
| +0.4% | +$1.37M | 0.01% | 1029 |
|
|
2022
Q2 | $288M | Buy |
7,183,692
+250,616
| +4% | +$8.79M | 0.01% | 1195 |
|
|
2022
Q1 | $259M | Buy |
6,933,076
+44,167
| +0.6% | +$1.7M | 0.01% | 1383 |
|
|
2021
Q4 | $274M | Buy |
6,888,909
+130,935
| +2% | +$5.01M | 0.01% | 1407 |
|
|
2021
Q3 | $251M | Buy |
6,757,974
+23,344
| +0.3% | +$959K | 0.01% | 1457 |
|
|
2021
Q2 | $285M | Buy |
6,734,630
+345,774
| +5% | +$14.8M | 0.01% | 1401 |
|
|
2021
Q1 | $303M | Buy |
6,388,856
+187,889
| +3% | +$11.2M | 0.01% | 1299 |
|
|
2020
Q4 | $378M | Buy |
6,200,967
+373,155
| +6% | +$22M | 0.01% | 1042 |
|
|
2020
Q3 | $272M | Buy |
5,827,812
+155,476
| +3% | +$7.65M | 0.01% | 1064 |
|
|
2020
Q2 | $288M | Buy |
5,672,336
+93,165
| +2% | +$4.58M | 0.01% | 1050 |
|
|
2020
Q1 | $249M | Buy |
5,579,171
+137,531
| +3% | +$6.92M | 0.01% | 1006 |
|
|
2019
Q4 | $261M | Buy |
5,441,640
+271,648
| +5% | +$11.5M | 0.01% | 1232 |
|
|
2019
Q3 | $175M | Buy |
5,169,992
+99,318
| +2% | +$4.32M | 0.01% | 1411 |
|
|
2019
Q2 | $228M | Buy |
5,070,674
+102,485
| +2% | +$4.05M | 0.01% | 1279 |
|
|
2019
Q1 | $187M | Buy |
4,968,189
+372,084
| +8% | +$12.5M | 0.01% | 1387 |
|
|
2018
Q4 | $158M | Buy |
4,596,105
+137,810
| +3% | +$4.96M | 0.01% | 1399 |
|
|
2018
Q3 | $210M | Buy |
4,458,295
+1,261,166
| +39% | +$52.2M | 0.01% | 1354 |
|
|
2018
Q2 | $108M | Buy |
3,197,129
+236,465
| +8% | +$7.37M | ﹤0.01% | 1740 |
|
|
2018
Q1 | $80.1M | Buy |
2,960,664
+185,009
| +7% | +$4.69M | ﹤0.01% | 1830 |
|
|
2017
Q4 | $46.3M | Sell |
2,775,655
-159,638
| -5% | -$2.7M | ﹤0.01% | 2096 |
|
|
2017
Q3 | $58.7M | Buy |
2,935,293
+568,729
| +24% | +$11.1M | ﹤0.01% | 1961 |
|
|
2017
Q2 | $43.4M | Buy |
2,366,564
+346,525
| +17% | +$4.67M | ﹤0.01% | 2080 |
|
|
2017
Q1 | $19.9M | Buy |
2,020,039
+101,331
| +5% | +$1.23M | ﹤0.01% | 2447 |
|
|
2016
Q4 | $20.9M | Buy |
1,918,708
+69,261
| +4% | +$727K | ﹤0.01% | 2404 |
|
|
2016
Q3 | $25.9M | Sell |
1,849,447
-480,355
| -21% | -$3.91M | ﹤0.01% | 2251 |
|
|
2016
Q2 | $16.4M | Buy |
2,329,802
+269,642
| +13% | +$1.98M | ﹤0.01% | 2413 |
|
|
2016
Q1 | $13.3M | Buy |
2,060,160
+13,784
| +0.7% | +$239K | ﹤0.01% | 2463 |
|
|
2015
Q4 | $66.3M | Buy |
2,046,376
+54,416
| +3% | +$1.6M | ﹤0.01% | 1744 |
|
|
2015
Q3 | $53.2M | Buy |
1,991,960
+271,569
| +16% | +$11.6M | ﹤0.01% | 1835 |
|
|
2015
Q2 | $82.8M | Buy |
1,720,391
+89,754
| +6% | +$5.24M | 0.01% | 1643 |
|
|
2015
Q1 | $99.2M | Buy |
1,630,637
+455,461
| +39% | +$27.8M | 0.01% | 1504 |
|
|
2014
Q4 | $60.8M | Buy |
1,175,176
+609,178
| +108% | +$26.8M | ﹤0.01% | 1727 |
|
|
2014
Q3 | $24.9M | Buy |
565,998
+17,194
| +3% | +$538K | ﹤0.01% | 2111 |
|
|
2014
Q2 | $14.3M | Buy |
548,804
+82,849
| +18% | +$1.77M | ﹤0.01% | 2354 |
|
|
2014
Q1 | $12.2M | Buy |
465,955
+318,506
| +216% | +$8.56M | ﹤0.01% | 2397 |
|
|
2013
Q4 | $2.5M | Buy |
147,449
+92,261
| +167% | +$1.62M | ﹤0.01% | 3101 |
|
|
2013
Q3 | $1.18M | Buy |
+55,188
| New | +$959K | ﹤0.01% | 3326 |
|
Other funds holding PTCT
RI
AC
Vanguard Group's PTCT Position: Q4 2025 in Review
Vanguard Group increased its PTC Therapeutics (PTCT) stake by 6.2% in Q4 2025, buying an estimated $37.4M and bringing the position to 8,803,203 shares worth $669M. The position accounts for 0.01% of the portfolio, ranked #882.
Vanguard Group first reported a position in PTCT in Q3 2013 and has held it in 50 quarters since. 353 funds tracked by Wall St. Rank hold PTCT as of Q4 2025.
- Vanguard Group held 8,803,203 shares of PTC Therapeutics worth $669M as of Q4 2025.
- Vanguard Group bought 514,204 PTC Therapeutics shares in Q4 2025, an estimated $37.4M.
- PTC Therapeutics made up 0.01% of Vanguard Group's portfolio in Q4 2025, its #882 holding.
- Vanguard Group first reported a position in PTC Therapeutics in Q3 2013 and has held it in 50 quarters since.
- 353 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.